Cadrenal Therapeutics Inc (CVKD)

[TacoTuesdayz]

LVAD patients face a high risk of bleeding events associated with oral anticoagulation alongside increased risk of cardiovascular (CV) events such as stroke

Hospitalization costs for patients following a major bleeding event associated with oral anticoagulation use averages $39,000 per event

Tecarfarin, with its novel metabolic pathway, potentially may offer an alternative to warfarin in this vulnerable population